Distribution of amyloid precursor protein and amyloid-β immunoreactivity in DBA/2J glaucomatous mouse retinas

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 11, 2007, Pages 5085-5090

  Goldblum, David ^a,b   Kipfer Kauer, Anna ^a   Sarra, Gian Marco ^a   Wolf, Sebastian ^a   Frueh, Beatrice E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; PARAFORMALDEHYDE; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DBA 2 MOUSE; DURA MATER; FEMALE; GLAUCOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROSCOPY; MOUSE; NONHUMAN; OPTIC NERVE; PIA MATER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; RETINA; STAINING; ANIMAL; C57BL MOUSE; DBA MOUSE; DISEASE MODEL; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; RETINA GANGLION CELL;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; DURA MATER; FEMALE; GLAUCOMA; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; OPTIC NERVE; PIA MATER; RETINA; RETINAL GANGLION CELLS;

EID: 38449122953     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1249     Document Type: Article

References (42)

1. Moya KL, Benowitz LI, Schneider GE, Allinquant B. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. Dev Biol. 1994;161(2):597-603.
2. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol. 1995;10(2):509-519.
3. Morimoto T, Ohsawa I, Takamura C, Ishiguro M, Nakamura Y, Kohsaka S. Novel domain-specific actions of amyloid precursor protein on developing synapses. J Neurosci. 1998;18(22):9386-9393.
4. Breen KC, Bruce M, Anderton BH. Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J Neurosci Res. 1991;28(1):90-100.
5. Dawson GR, Seabrook GR, Zheng H, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90(1):1-13.
6. Morin PJ, Abraham CR, Amaratunga A, et al. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem. 1993;61(2):464-473.
7. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766.
8. Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci. 1993;695:144-148.
9. Verbeek MM, de Waal RMW, Vinters HV. Chemical analysis of amyloid β protein in CAA. In: Verbeek MM, de Waal RMW, Vinters HV, eds. Cerebral Amyloid Angiopathy in Alzheimer's Disease and Related Disorders. Amsterdam: Kluwer Academic Publishers; 2000:157-177.
10. Roher AE, Kuo YM, Roher AA, et al. Immunohistochemical analysis of amyloid β protein isoforms in CAA. In: Verbeek MM, de Waal RMW, Vinters HV, eds. Cerebral Amyloid Angiopathy in Alzheimer's Disease and Related Disorders. Amsterdam: Kluwer Academic Publishers; 2000:179-188.
11. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32(18):4693-4697.
12. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002;47(3):165-168.
13. Janciauskiene S, Krakau T. Alzheimer's peptide: a possible link between glaucoma, exfoliation syndrome and Alzheimer's disease. Acta Ophthalmol Scand. 2001;79(3):328-329.
14. John SW, Smith RS, Savinova OV, et al. Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci. 1998;39(6):951-962.
15. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997; 94(24):13287-13292.
16. McKinnon SJ. Glaucoma: ocular Alzheimer's disease? Front Biosci. 2003;8:1140-1156.
17. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43(4):1077-1087.
18. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984;122(3):1131-1135.
19. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885-890.
20. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994;145(2):452-460.
21. Martin KRG, Quigley HA, Valenta D, Kielczewski D, Pease ME. Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma. Exp Eye Res. 2006;83(2):255-262.
22. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature. 2001; 414:643-648.
23. Vickers JC. The cellular mechanism underlying neuronal degeneration in glaucoma: parallels with Alzheimer's disease. Aust N Z J Ophthalmol. 1997;25(2):105-109.
24. Straznicky C, Vickers JC, Gabriel R, Costa M. A neurofilament protein antibody selectively labels a large ganglion cell type in the human retina. Brain Res. 1992;582(1):123-128.
25. Vickers JC, Delacourte A, Morrison JH. Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease. Brain Res. 1992;594(2):273-278.
26. Vickers JC, Riederer BM, Marugg RA, et al. Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease. Neuroscience. 1994;62(1):1-13.
27. Vickers JC, Costa M. The neurofilament triplet is present in distinct subpopulations of neurons in the central nervous system of the guinea-pig. Neuroscience. 1992;49(1):73-100.
28. Rohn TT, Head E, Su JH, et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol. 2001;158(1):189-198.
29. Vickers JC, Schumer RA, Podos SM, Wang RF, Riederer BM, Morrison JH. Differential vulnerability of neurochemically identified subpopulations of retinal neurons in a monkey model of glaucoma. Brain Res. 1995;680(1-2):23-35.
30. Perry V. Evidence for an amacrine cell system in the ganglion cell layer of the rat retina. Neuroscience. 1981;6:931-944.
31. Vinters HV, Vonsattel JPG. Neuropathologic features and grading of Alzheimer-related and sporadic CAA. In: Verbeek MM, de Waal RMW, Vinters HV, eds. Cerebral Amyloid Angiopathy in Alzheimer's Disease and Related Disorders. Amsterdam: Kluwer Academic Publishers; 2000:137-155
32. Gervais FG, Xu D, Robertson GS, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999;97(3):395-406.
33. Barnes NY, Li L, Yoshikawa K, Schwartz LM, Oppenheim RW, Milligan CE. Increased production of amyloid precursor protein provides a substrate for caspase-3 in dying motoneurons. J Neurosci. 1998;18(15):5869-5880.
34. Uetsuki T, Takemoto K, Nishimura I, et al. Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J Neurosci. 1999;19(16):6955-6964.
35. Weidemann A, Paliga K, Durrwang U, et al. Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. J Biol Chem. 1999;274(9):5823-5829.
36. Marin N, Romero B, Bosch-Morell F, et al. Beta-amyloid-induced activation of caspase-3 in primary cultures of rat neurons. Mech Ageing Dev. 2000;119(1-2):63-67.
37. Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76(1):173-181.
38. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5(6):780-787.
39. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916-919.
40. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98(15):8850-8855.
41. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177.
42. Wilcock DM, Gordon MN, Ugen KE, et al. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 2001;20(11):731-736.